Drugs / ATG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05917405 Background | Sep 2023 → Sep 2028 expected | acute myeloid leukemia | Nantes University Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05917405 ↗ |
| Route | Intravenous | “Thymoglobuline®: 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)” NCT05917405 ↗ |